Related Experiment Video
Updated: Dec 28, 2025
Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients
Published on: September 25, 2018
Molecular regulatory network of PD-1/PD-L1 in non-small cell lung cancer
Zhu Lingling1, Liu Jiewei1, Wang Li1
1Lung Cancer Center, West China Hospital of Sichuan University, Chengdu, Sichuan, PR China.
Abstract:
Lung cancer remains the most common cancer and the leading cause of cancer death worldwide. Despite effective chemotherapy and molecular-based therapies, the median and overall survival remains poor. Immune checkpoint inhibitors have changed the treatment landscape for patients with non-small cell lung cancer (NSCLC) by inhibiting negative T cell regulators, including programmed death 1 (PD-1, CD279) and programmed death ligand 1 (PD-L1, also known as B-H1, CD274) inhibitors. Nonetheless, most patients do not respond to these inhibitors. Recently, PD-L1 expression has been demonstrated to influence the anti-tumor efficacy of immune checkpoint inhibitors. However, the mechanisms of PD-L1 regulation are not clearly understood. This review thus aims to summarize the current knowledge and recent developments in the regulatory mechanisms of PD-L1 expression levels and attempts to clarify its latent function in anti-tumor activity, with the goal of guiding better designs for future NSCLC immunotherapies.
Insights
Lung cancer survival is poor despite therapies. This review explores programmed death ligand 1 (PD-L1) regulation, crucial for improving immune checkpoint inhibitor effectiveness in non-small cell lung cancer (NSCLC) treatment.
Area of Science:
- Oncology
- Immunology
- Cancer Research
Background:
- Lung cancer is a leading cause of cancer death globally.
- Current therapies offer limited survival benefits for many non-small cell lung cancer (NSCLC) patients.
- Immune checkpoint inhibitors (ICIs) show promise but lack efficacy in most patients.
Purpose of the Study:
- To review current knowledge on programmed death ligand 1 (PD-L1) expression regulation.
- To clarify the role of PD-L1 in anti-tumor activity.
- To guide future NSCLC immunotherapy development.
Main Methods:
- Literature review of regulatory mechanisms of PD-L1 expression.
- Analysis of PD-L1's function in anti-tumor immunity.
- Synthesis of findings to inform immunotherapy strategies.
Main Results:
- PD-L1 expression impacts ICI efficacy in NSCLC.
- Mechanisms regulating PD-L1 levels are not fully understood.
- Understanding PD-L1 regulation is key to overcoming ICI resistance.
Conclusions:
- Further research into PD-L1 regulation is essential.
- Clarifying PD-L1's role can enhance NSCLC immunotherapy.
- Targeting PD-L1 regulation may improve patient outcomes.
More Related Videos
Related Concept Videos
02:39lncRNA - Long Non-coding RNAs
01:19Interactions Between Signaling Pathways
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
02:23Abnormal Proliferation
01:23Negative Regulator Molecules